Schizophrenia, "just the facts" 4. Clinical features and conceptualization
- PMID:19328655
- DOI: 10.1016/j.schres.2009.03.005
Schizophrenia, "just the facts" 4. Clinical features and conceptualization
Abstract
Although dementia praecox or schizophrenia has been considered a unique disease entity for the past century, its definitions and boundaries have continued to vary over this period. At any given time, the changing concept of schizophrenia has been influenced by available diagnostic tools and treatments, related conditions from which it most needs to be distinguished, extant knowledge and scientific paradigms. There is significant heterogeneity in the etiopathology, symptomatology, and course of schizophrenia. It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness. Positive symptoms usually first begin in adolescence or early adulthood, but are often preceded by varying degrees of negative and cognitive symptomatology. Schizophrenia tends to be a chronic and relapsing disorder with generally incomplete remissions, variable degrees of functional impairment and social disability, frequent comorbid substance abuse, and decreased longevity. Although schizophrenia may not represent a single disease with a unitary etiology or pathogenetic process, alternative approaches have thus far been unsuccessful in better defining this syndrome or its component entities. The symptomatologic, course, and etio-pathological heterogeneity can usefully be addressed by a dimensional approach to psychopathology, a clinical staging approach to illness course, and by elucidating endophenotypes and markers of illness progression, respectively. This will allow an approach to the deconstruction of schizophrenia into its multiple component parts and strategies to reconfigure these components in a more meaningful manner. Possible implications for DSM-V and ICD-11 definitions of schizophrenia are discussed.
Comment in
- Newer conceptualizations of schizophrenia demand a name change.Levin TT.Levin TT.Schizophr Res. 2009 Dec;115(2-3):374. doi: 10.1016/j.schres.2009.09.013. Epub 2009 Oct 2.Schizophr Res. 2009.PMID:19800202No abstract available.
- The facts of schizophrenia: a personal commentary.Carpenter WT.Carpenter WT.Schizophr Res. 2011 May;128(1-3):3-4. doi: 10.1016/j.schres.2011.03.002. Epub 2011 Apr 1.Schizophr Res. 2011.PMID:21458240No abstract available.
Similar articles
- Nosological status and definition of schizophrenia: Some considerations for DSM-V and ICD-11.Tandon R, Maj M.Tandon R, et al.Asian J Psychiatr. 2008 Dec;1(2):22-7. doi: 10.1016/j.ajp.2008.10.002. Epub 2008 Nov 25.Asian J Psychiatr. 2008.PMID:23050991
- Beyond the facts in schizophrenia: closing the gaps in diagnosis, pathophysiology, and treatment.Nasrallah H, Tandon R, Keshavan M.Nasrallah H, et al.Epidemiol Psychiatr Sci. 2011 Dec;20(4):317-27. doi: 10.1017/s204579601100062x.Epidemiol Psychiatr Sci. 2011.PMID:22201209Review.
- [Psychopathology of schizophrenia and brain imaging].Gross G, Huber G.Gross G, et al.Fortschr Neurol Psychiatr. 2008 May;76 Suppl 1:S49-56. doi: 10.1055/s-2008-1038152.Fortschr Neurol Psychiatr. 2008.PMID:18461545Review.German.
- [Diagnosing schizophrenia: from Bleuler to DSM-V].Réthelyi J.Réthelyi J.Neuropsychopharmacol Hung. 2011 Dec;13(4):193-203.Neuropsychopharmacol Hung. 2011.PMID:22184187Review.Hungarian.
- [A hundred years of schizophrenia: from Bleuler to DSM-V].Blom JD.Blom JD.Tijdschr Psychiatr. 2007;49(12):887-95.Tijdschr Psychiatr. 2007.PMID:18175290Dutch.
Cited by
- Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations.Alasmari MS, Alasmari F, Alasmari AF, Alshamsan A, Alsanea S, Rasool MF, Alqahtani F.Alasmari MS, et al.Pharmaceutics. 2022 Aug 26;14(9):1795. doi: 10.3390/pharmaceutics14091795.Pharmaceutics. 2022.PMID:36145543Free PMC article.
- Psychotic relapse in people with schizophrenia within 12 months of discharge from acute inpatient care: protocol for development and validation of a prediction model based on a retrospective cohort study in three psychiatric hospitals in Japan.Sato A, Watanabe N, Maruo K, Moriyama T, Furukawa TA.Sato A, et al.Diagn Progn Res. 2022 Nov 3;6(1):20. doi: 10.1186/s41512-022-00134-w.Diagn Progn Res. 2022.PMID:36324165Free PMC article.
- Associations between purine metabolites and monoamine neurotransmitters in first-episode psychosis.Yao JK, Dougherty GG, Reddy RD, Matson WR, Kaddurah-Daouk R, Keshavan MS.Yao JK, et al.Front Cell Neurosci. 2013 Jun 11;7:90. doi: 10.3389/fncel.2013.00090. eCollection 2013.Front Cell Neurosci. 2013.PMID:23781173Free PMC article.
- Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations.Thokagevistk K, Millier A, Lenert L, Sadikhov S, Moreno S, Toumi M.Thokagevistk K, et al.J Mark Access Health Policy. 2016 Jun 20;4. doi: 10.3402/jmahp.v4.30725. eCollection 2016.J Mark Access Health Policy. 2016.PMID:27386054Free PMC article.
- White matter alterations in first episode treatment-naïve patients with deficit schizophrenia: a combined VBM and DTI study.Lei W, Li N, Deng W, Li M, Huang C, Ma X, Wang Q, Guo W, Li Y, Jiang L, Zhou Y, Hu X, McAlonan GM, Li T.Lei W, et al.Sci Rep. 2015 Aug 10;5:12994. doi: 10.1038/srep12994.Sci Rep. 2015.PMID:26257373Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous